(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) ...

The White House said Friday it’s adding three drugs for diabetes and lung disease to the self-pay platform TrumpRx, as the ...

The first-in-class injectable could be the next big thing in diabetes and obesity treatment.

Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and ...

Lilly’s experimental drug met endpoints for blood-sugar level reduction and weight loss at trial.

Drugs such as semaglutide may be useful for mental health conditions associated with diabetes, authors say ...

SELECT was a large study focused on obesity and cardiovascular disease in people without type 2 diabetes, but it included kidney outcomes as a secondary end point. The data showed that semaglutide ...

From online forums to the clinic, people have reported that diabetes and weight-loss drugs such as Ozempic and Wegovy can dramatically quell their compulsive behaviors—including cravings for alcohol ...

GLP-1 medications used to treat diabetes and obesity were associated with a reduced need for hospital care and sickness ...

People who quit taking popular GLP-1 drugs such as Ozempic might their jeopardize heart health, according to a new study.

A new study suggests that almost half of people stopping GLP-1 weight-loss drugs may keep the weight off. However, many of these people continued other forms of treatment after stopping GLP-1 drugs.

Metformin use in people with diabetes was linked to a significantly lower risk of developing intermediate age-related macular degeneration.